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Abstract
Epstein-Barr virus (EBV) is able to drive the transformation of B-cells, resulting in the generation of lymphoblastoid cell lines
(LCLs) in vitro. EBV nuclear proteins EBNA3A and EBNA3C are necessary for efficient transformation, while EBNA3B is
dispensable. We describe a transcriptome analysis of BL31 cells infected with a series of EBNA3-knockout EBVs, including
one deleted for all three EBNA3 genes. Using Affymetrix Exon 1.0 ST microarrays analysed with the MMBGX algorithm, we
have identified over 1000 genes whose regulation by EBV requires one of the EBNA3s. Remarkably, a third of the genes
identified require more than one EBNA3 for their regulation, predominantly EBNA3C co-operating with either EBNA3B,
EBNA3A or both. The microarray was validated by real-time PCR, while ChIP analysis of a selection of co-operatively
repressed promoters indicates a role for polycomb group complexes. Targets include genes involved in apoptosis, cell
migration and B-cell differentiation, and show a highly significant but subtle alteration in genes involved in mitosis. In order
to assess the relevance of the BL31 system to LCLs, we analysed the transcriptome of a set of EBNA3B knockout (3BKO) LCLs.
Around a third of the genes whose expression level in LCLs was altered in the absence of EBNA3B were also altered in 3BKO-
BL31 cell lines. Among these are TERT and TCL1A, implying that EBV-induced changes in the expression of these genes are
not required for B-cell transformation. We also identify 26 genes that require both EBNA3A and EBNA3B for their regulation
in LCLs. Together, this shows the complexity of the interaction between EBV and its host, whereby multiple EBNA3 proteins
co-operate to modulate the behaviour of the host cell.
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Introduction
Epstein-Barr virus (EBV) is ubiquitous in the human population,
with up to 95% of humans asymptomatically infected. In vitro, EBV
can very efficiently induce the activation and continuous
proliferation of resting human B cells. The resulting lymphoblas-
toid cell lines (LCLs) carry the viral genome as extra-chromosomal
episomes and express only nine ‘latent’ EBV proteins in the
latency III or ‘growth program’ of viral gene expression. This
program is comprised of six nuclear antigens (EBNAs 1, 2, 3A, 3B,
3C & LP), three membrane associated proteins (LMP1, LMP2A &
2B) and also several untranslated RNA species [1,2]. The
uncontrolled proliferation driven by latency III is also seen
transiently in vivo. In the absence of effective cytotoxic T-cell
surveillance, an aggressive B-lymphoproliferative disease (post-
transplant lymphoproliferative disease; PTLD) or, rarely, malig-
nant lymphomas may arise [3].
In humans, it is now considered probable that to establish
persistence, EBV initially infects resting (naı ¨ve) B cells and drives
these to proliferate as activated B-blasts, much as occurs in vitro.
Infected B-blasts then migrate into germinal centres and
differentiate to eventually become resting memory B cells [4,5].
This differentiation process is coupled to a progressive shut-down
of EBV gene expression from the growth-promoting latency III
state achieved in vitro, to the latency II program seen in germinal
centre cells [6] and ending in the establishment of resting memory
B cells in which no latent proteins are expressed.
Generally only expressed during latency III, EBNA3A,
EBNA3B and EBNA3C comprise a protein family with no known
homologues outside the primate lymphocryptoviruses. They share
a gene structure (each having a short 59 exon and longer 39 exon)
and occur as a tandem array in the EBV genome, having a limited
amino acid sequence homology. Together with the other EBNAs,
the EBNA3 transcripts are alternatively spliced from very long
mRNAs generally initiated at the Cp latency promoter; LCLs have
only a few copies of these transcripts per cell, suggesting their
expression is tightly regulated and the turnover of the EBNA3s is
slow [7].
Along with EBNA2 and LMP1, EBNA3A and EBNA3C were
identified as essential for the transformation of B cells into LCLs
[8,9], although more recently an EBNA3A-deleted EBV has been
used to transform B cells, albeit with reduced efficiency. It seems
likely that EBNA3A (acting with EBNA3C) facilitates LCL
outgrowth through the epigenetic repression of the p16
INK4A gene
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retinoblastoma (Rb) pathway [10,11]. In contrast, EBNA3B is
entirely dispensable for generating LCLs [12,13].
EBNA2, the major transcriptional activator of latency III, is
primarily directed to genes by its binding to the DNA-binding
factor CBF1 (RBPJk) [14]. All the EBNA3 proteins also bind to the
same region of CBF1, can all inhibit EBNA2-mediated activation
of the LMP2 and Cp promoters [15,16,17,18,19]. Additionally, all
of the EBNA3s exhibit robust repressor activity when targeted
directly to DNA [18,20,21,22] . They are all known to interact
with one or more cellular factors involved in transcriptional
repression or silencing, including histone deacetylases (HDACs)
and C-terminal binding protein (CtBP) [21,23,24,25].
We have recently explored the mechanism of transcriptional
repression of both the pro-apoptotic protein Bim and the cell cycle
inhibitor p16
INK4A by EBNA3A and EBNA3C. In both cases the
EBNA3-dependent epigenetic change associated with repression is
the trimethylation of lysine 27 on histone H3 (H3K27Me3)
[11,26]. In the case of p16
INK4A, this is dependent on the binding
of EBNA3A and EBNA3C to CtBP [11]. This epigenetic
modification is established and repression is maintained by the
action of the polycomb group of proteins (PcG) [27].
In addition to their role in transcriptional repression, EBNA3A
and EBNA3C are known to play a role in the regulation of the cell
cycle. A number of studies assert that EBV overrides or modifies
cell cycle checkpoints in G1, G2 and mitosis (reviewed in O’Nions
and Allday [28]). Consistent with the ability to override cell cycle
checkpoints, it has been observed that genomic instability is
increased by latent EBV [29], and is probably attributable in part
to the ability of EBNA3C to override a mitotic spindle checkpoint
[30].
EBNA3C and EBNA3A are able to co-operate with oncogenic
ras (Ha-ras) in transforming embryonic rat fibroblasts (which again
requires CtBP interaction), and when over expressed EBNA3C
can overcome a mitotic checkpoint [21,31,32]. Additionally,
EBNA3C has been reported to bind to a number of cell-cycle
regulators, including cyclin A, SCF
SKP2, pRb, Myc, p53 and
MDM2 [24,33,34,35,36,37,38].
In order to understand the transcriptional targets of the EBV
proteins, a number of microarray studies have now been
undertaken to investigate their transcriptional targets. However,
these studies are limited by their narrow scope, typically focusing
on individual proteins outside the context of other EBV gene
products, and being undertaken in a wide range of different cell
backgrounds. As a consequence, the agreement between studies is
typically very limited (reviewed by Calderwood and Johannsen
[39]). In contrast to EBNA2 and LMP1, there are few published
microarray studies looking at the impact of the EBNA3s on host
gene expression [10,40,41]. Therefore in order to properly
understand the interaction of the EBNA3 proteins with host cells,
we have generated independent knockouts of EBNA3A, EBNA3B
and EBNA3C in the context of the B95-8 BAC system [42]. A
similar approach has been used to investigate mutants of EBNA3A
[10], and to generate a mutant lacking EBNA3B which is impaired
for EBNA3C expression [40].
Since EBNA3C is essential for immortalisation of B-cells, we
cannot produce LCLs with all of our virus mutants. However, de
novo infection of EBV-negative BL cells results in the latency III
gene expression profile which produces a phenotypic alteration of
the cell to a more LCL-like phenotype [43,44]. We have therefore
adopted the BL31 cell line as a platform for comparing the
function of various EBV proteins, by generating cell lines infected
by various EBV mutants. To maximise the benefit of this system,
we have undertaken a transcriptional analysis using the Affymetrix
Exon 1.0 ST microarray platform on the various virus mutants,
which has probes for almost all human genes. This study
demonstrates the value of a co-ordinated approach to assessing
the roles of the EBV genes and proteins, showing extensive co-
operation between the EBNA3s in altering host gene transcription,
and identifying a number of genes consistently modulated by EBV,
which may play key roles in effecting the biological imperatives of
the virus.
Results
Microarray strategy
We have previously reported the generation of mutant EBVs
lacking either the EBNA3A, 3B or 3C gene, and the production of
BL31 cell lines carrying these mutants [42]. These mutants were
generated in the EBV-BAC (or Maxi-EBV) system [45] and
revertants (where the targeted mutation has been restored to wild-
type sequence) generated for each EBV mutant. We have
additionally constructed a virus lacking the entire EBNA3 locus
(E3KO), and its revertant (E3rev). BL31 cells infected with E3KO
grew out poorly and unlike the single gene knockouts reported
previously, the cells retain a requirement for supplements (a-
thioglycerol and sodium pyruvate) in the medium. In order to
make valid comparisons between the wild-type-infected, knock-
outs, and parental BL31 cells, we therefore generated a further set
of cell lines which we grew out in the presence of the supplements
used to support the parental BL31 cells. As with our previously
published single EBNA3 knockout BL31 cell lines, there is no
consistent difference in the expression of other EBV genes between
the mutant and wild-type-infected cells (Figure S1).
RNA extracted from three or four cell lines for each mutant
group (3AKO, 3BKO, 3CKO and E3KO), from two or three lines
for each corresponding revertant and the parental EBV-BAC
(wtBAC), and three times from the parental BL31 line was used to
generate transcriptome information using Affymetrix Human
Exon 1.0 ST microarrays, analysed by MMBGX [46] to interpret
this at the gene and transcript level.
EBNA3 genes co-operatively regulate host genes
Principal component analysis and hierarchical clustering both
show that the different EBV mutants generally segregate together
according to their gene expression profile (Figure S2). The main
exception to this is the EBNA3A mutants, two of which cluster
with the mutants and two on the edge of the wild-type group. The
reason for this heterogeneity is not clear, although it reflects the
time at which the cell lines were generated, and the consequence is
to reduce the number of genes passing any statistical threshold,
reducing the number of genes apparently regulated by EBNA3A.
We identified differences in gene expression level by analysis of
variance (ANOVA), using contrasts of each mutant (and
uninfected BL31) with the wtBAC-infected cell lines (including
revertants) (Table S1). False discovery rate (FDR) analysis on the
p-values for the contrasts implied that an unadjusted p-value of
around 0.001 would offer sufficient statistical confidence. Addi-
tionally, there was no statistically significant difference between
any revertant group and the rest of the wild-type lines.
Using a fold-change of 2 as an arbitrary threshold, along with a
p-value of ,0.001 we established lists of genes differentially
regulated by each of the EBNA3s. Deleting EBNA3C has the
greatest impact on the regulation of host genes, with 839 genes
affected. In contrast the 3BKO cells showed 598 differentially
regulated genes, with 210 differentially regulated in the absence of
EBNA3A. For each mutant, the numbers of genes up- and down-
regulated are fairly similar (in a ratio of 2:3 for 3AKO and
Gene Regulation by EBV EBNA3s
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knockouts shows a large overlap in genes deregulated by deletion
of a single EBNA3 gene (Figure 1A). For each set of genes (3AKO,
3BKO or 3CKO) only around half are unique to that set – for
instance, 101 of the 210 genes altered in 3AKO BL31 are also
significantly altered in at least one of 3BKO or 3CKO BL31 cells.
It is striking that EBNA3B, dispensable for the immortalisation of
B-cells by EBV, and currently regarded as a minor player in EBV
biology, is required for the repression of almost as many genes as
EBNA3C, and indeed co-operates with EBNA3C in altering the
regulation of about half of these. In contrast, the overlap with
EBNA3A in gene repression is much more modest, with few genes
solely requiring EBNA3A and 3C (such as BCL2L11/BIM)o r3 A
and 3B for their regulation. Indeed where 3A and 3C are involved
in gene repression, the norm appears to be that EBNA3B is also
required.
In the genes up-regulated by EBV (and thus at reduced levels in
the knockouts) a similar pattern of co-operation emerges, although
EBNA3C plays a more dominant role. Here, there is less of a role
for EBNA3B alone or combined with EBNA3A, and a greater role
for the combination of EBNA3A and 3C, and for EBNA3C alone.
The inference of this might be that EBNA3C is more of a
transcriptional activator than EBNA3B but the steady state nature
of this system makes such inferences speculative at best. However,
it does suggest that the EBNA3s work as a concerted whole, with
390 of the 1201 differentially regulated genes requiring multiple
EBNA3s in this system.
Taking the group of 1201 genes that are differentially regulated
between the single knockouts and wild-type cells, we looked at how
many were also differentially regulated between either BL31 and
wild-type or triple knockout (E3KO) and wild-type (Figure 1B).
Around half of the genes whose expression is altered by infection
of BL31 by EBV require at least one of the EBNA3s for at least
some component of their regulation. Conversely, only around half
of the genes identified as differentially regulated in the single
EBNA3 knockouts are also seen in either the E3KO or BL31
contrasts. This may be partly a consequence of setting significance
thresholds that fail genes due to the smaller size for the E3KO and
BL31 groups (3 samples each).
To assess the validity of our microarray data, we undertook
PCR analysis of 42 genes, of which 5 were used as endogenous
controls to normalise the samples. Plotting the relative quantity as
determined by qPCR against the MMBGX gene level estimate
(Figure 2), there is generally a good correlation between
Figure 1. Overlap of genes differentially expressed by EBV mutant BL31 cells. Each set in the Venn diagram contains the number of genes
defined as differentially regulated (p value ,0.001 and fold change .2) for the mutant group shown as compared to wtBAC-infected BL31. The total
number of genes in the set is indicated below the set’s identity. A. Numbers of genes differentially regulated in different combinations of EBNA3
knockout virus-infected BL31 cell lines are indicated. B. The combined group of genes falling in the venn diagrams from A (group 3A/3B/3C) is
compared with genes differentially regulated between wtBAC-BL31s and E3KO-BL31s (bottom left set) or uninfected BL31 (bottom right set). Up-
regulated vs WT (left side Venn diagrams) indicates genes whose expression was higher in the mutant-infected/uninfected BL31s than wtBAC-
infected BL31s; down-regulated vs WT indicates lower expression in these lines.
doi:10.1371/journal.pone.0013979.g001
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microarray corresponds to a 2.7-fold change by qPCR. The main
deviations from this trend are either: a) where the transcript level
fell below the detectable threshold for the qPCR assay, mainly
where the microarray log2 expression value ,3; b) for the GAPDH
and ACTB endogenous control assays, which appear to be more
efficient qPCR assays than the others; and c) the SOX4 qPCR
assay, which measured a lower expression level than the
microarray but, upon inspection, had an inferior amplification
profile (not shown). This suggests that the microarray gene level
estimates are a generally accurate reflection of transcript level in
the cell population.
Functional groups enriched in EBNA3-mutant BL31 cells
To explore what classes of genes were regulated by the EBNA3
genes in BL31 cells, we used the online ontology resource,
DAVID. In order to avoid missing biological relationships
because of the arbitrary nature of the cut-offs used to generate
gene lists, we compiled additional lists of up and down-regulated
genes for each of the EBNA3 knockouts, using more stringent p-
value criteria (,0.0001) for smaller fold-changes (.1.3). The
most striking observation was the enrichment of genes up-
regulated in the 3CKO BL31 cells for the GOTERM-BP ‘cell
cycle’ with a q-value significance of 6.8610
225. Highly significant
enrichments were also seen for ‘mitosis’ and ‘M-Phase’,
‘chromosome organisation’ (mainly histone clusters) and ‘cyto-
skeleton’, suggesting that this alteration is related to mitosis.
Curiously, where the fold-change threshold is increased to 2, no
significant enrichment of these ontological groups is observed.
Enrichment of these categories is also seen for 3BKO up-
regulated genes, but only for the subset co-regulated by
EBNA3C.
Functional clustering analysis indicated additional biological
processes that may be altered by the deletion of the EBNA3 genes.
These are involved with the processes of cell migration/
locomotion/chemotaxis, lymphocyte activation and differentia-
tion, and apoptosis and its regulation – the statistics for enrichment
of these clusters for the various mutant groups (with up-and down-
regulated genes for each mutant treated both as separate gene sets
and as a single group) are detailed in Table S2. Viewing the
expression profiles of the genes in these clusters (Figure 3) the co-
operative nature of the EBNA3s in manipulating host gene
expression is evident. Taken overall, the large number of genes co-
regulated by EBNAs 3B and 3C is clear, while individual genes
regulated by other combinations can be easily picked out. For
instance, BIM (BCL2L11 - towards bottom of apoptosis heat map)
whose expression in 3AKO and 3CKO BL31 cells correlates with
susceptibility to apoptotic stimuli is expressed similarly to CADM1
and FGD4.
EBNA3 deletion alters expression levels of genes involved
in B-cell differentiation
Since different patterns of EBV gene expression are known to be
coupled to the differentiation state of the host B cell, we examined
the gene expression profiles of 21 transcription factors associated
with the B cell differentiation process [47,48,49]). Of these, 17
were altered at the transcript level by EBV, and many required
one or more of the EBNA3s for this regulation (Figure 4). Notably,
BCL6, NFATC2 and BACH2 exhibit more than a 10-fold increase
in RNA levels in one or more mutant and EBV infection also alters
EBF1 and STAT5A more than five-fold (Table S3).
Additionally, we performed gene set enrichment analysis
(GSEA) for EBV- and EBNA3-regulated genes among those
whose expression changes through the germinal centre transition
Figure 2. Validation of microarray expression level data by qPCR. The log2-transformed gene expression values of 42 genes were
established for 16 of the BL31 cell lines, by qPCR analysis of the RNA samples previously used for the microarrays. These are plotted against the
corresponding gene-level expression value from the MMBGX microarray analysis. Correlation coefficient and best-fit line are shown. Assays deviating
from this trendline (GAPDH, ACTB and SOX4) are coloured as indicated. TERT is included for comparison with LCL data (Figure S4).
doi:10.1371/journal.pone.0013979.g002
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PLoS ONE | www.plosone.org 4 November 2010 | Volume 5 | Issue 11 | e13979Figure 3. Relative expression of differentially regulated genes falling into significant ontological groups. MMBGX-extracted gene
expression levels were normalised to the mean and scaled by the standard deviation of the gene expression level for each gene – colour coding
ranges from +2t o22 standard deviations (see scale bottom left). These were grouped by ontological term, and where genes fell into multiple
groups, they were placed in the group in the following order – Mitosis, apoptosis, cell migration, hemopoesis and activation. Genes within each
group were ordered by unsupervised clustering.
doi:10.1371/journal.pone.0013979.g003
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phenotype away from that of a germinal centre cell, and that
EBNA3C is required for the modulation of some of these genes.
EBNA3B deletion results in the up-regulation of a subset of genes
that are normally more repressed in the germinal centre, but does
not significantly affect genes up-regulated in the germinal centre
(see Supporting Information File S1 and Table S4 for full
description).
Epigenetic promoter modifications reflect expression
changes
In order to further validate the observations from our
microarray we selected individual genes that represented the
different co-regulated groups for the microarray. Since the
designation of a gene to any group is based on partially arbitrary
cut-offs, we selected genes that convincingly fell into each group,
having the same change in expression level for each mutant, as
well as clearly exhibiting no change for the other mutant group.
We immunoprecipitated chromatin modified by trimethylation of
lysines 4 and 27 and acetylation of lysine 9 of histone H3
(H3K4Me3, H3K27Me3 and H3K9Ac respectively), and used
qPCR directed at regions around the gene promoter to identify the
chromatin modifications at each promoter. The genes used were
NOTCH2 for EBNA3A/3C co-regulated (Figure 5); RASGRP1 for
3B/3C (Figure 6) and TOX for 3A/3B/3C (Figure 7). Each figure
shows the microarray data (A) confirmation of gene expression by
qPCR (B) and the ChIP data (C) with the position of the ChIP
qPCR assays indicated below.
For NOTCH2, RASGRP1 and TOX, we can clearly see an
inverse correlation between expression and trimethylation of
H3K27. For instance, the derepression of NOTCH2 in 3AKO and
3CKO-BL31 cell lines is accompanied by a corresponding
reduction in H3K27 trimethylation. Similarly, RASGRP1 has less
H3K27Me3 in 3BKO and 3CKO BL31, and TOX only has
appreciable levels of H3K27Me3 in the wtBAC-BL31 cell lines. In
contrast, H3K4 trimethylation of the promoters, generally a mark
of transcriptionally active genes, is largely unchanged between the
cell lines, while H3K9 acetylation correlates with increased
expression of TOX and RASGRP1, but is unchanged on the
NOTCH2 promoter. The significance of these epigenetic combi-
nations is considered below.
A subset of genes is differentially expressed in both
3BKO-LCLs and 3BKO BL31 cell lines
In order to see to what extent our observations transfer beyond
the BL31 cell line, we investigated the effect of EBNA3B deletion
in LCLs, as EBNA3B is known to be dispensable for B cell
immortalisation [12]. Using the 3BKO and wtBAC viruses, we
established two independent LCLs in lymphocytes from each of
three independent EBV-negative blood donors. The 3BKO-LCLs
established efficiently, perhaps more readily than wtBAC LCLs,
and analysis of EBV latent protein levels showed that other than
the loss of EBNA3B expression, EBV proteins did not differ
substantially between wtBAC-LCL and 3BKO-LCLs (Figure S3).
RNA harvested from these lines between 3–6 weeks after infection
was analysed on Affymetrix Human Exon 1.0 ST microarrays. A
2-way ANOVA model incorporating the donor ID (representing
the three different genetic backgrounds of the transformed cells) as
the additional factor revealed considerable gene expression
changes between wtBAC and 3BKO LCLs (Table S5). A p-value
of 0.0004-7 corresponded to a 5% FDR but, for a more
representative comparison with the BL31s, we have used a p-
value of 0.001 as a statistical threshold in our analysis.
Analysis of gene expression levels by qPCR again showed a high
degree of correlation with gene expression values from the
microarray (Figure S4), with the same outlying assays (ACTB,
Figure 4. EBV and EBNA3s alter the expression of B-cell differentiation-related transcription factors. Heat map shows the relative
expression levels of key transcription factors involved in B-cell differentiation. MMBGX-extracted gene expression levels were normalised to the mean
and scaled by the standard deviation of the gene expression level for each gene – colour scale ranges from +2t o22 standard deviations. Genes are
grouped according to whether they are up- or down-regulated upon infection by EBV. Those not significantly altered are also indicated. Fold change
and ANOVA contrast p values for these genes are shown in Figure S2.
doi:10.1371/journal.pone.0013979.g004
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TERT mRNA was often undetectable by qPCR in the wtBAC
LCLs, while the microarray implies a modest down-regulation.
Since this observation was true for five independent TERT qPCR
assays spanning different exon junctions (Figure S5 A-D), it
suggests that the microarray signal for this gene is artificially high
in these cells, or that the amplification of the transcript is somehow
prevented.
Comparing the genes regulated by EBNA3B in LCLs with those
of BL31, we see only a modest overlap (Figure 8; Table S6). Of the
89 genes requiring EBNA3B for their repression in LCLs, 14 are
also repressed in BL31s, while of the 108 genes up-regulated in
3BKO LCLs, 32 are also up-regulated in BL31-3BKO. A further
eight of the genes that are down-regulated in 3BKO LCLs are up-
regulated in BL31s. Of these eight genes, four (ARID5B, CD72,
RUNX1, TNFSF10) are also significantly altered during the naı ¨ve
to centroblast transition of the germinal centre reaction, and a
further 3 are not uniquely represented on the U133 microarray
used in that experiment [50]. Taken together, this shows that some
25% of EBNA3B-regulated genes in LCLs also require EBNA3B
for their regulation in BL31.
In common with the analysis of gene ontology enrichment in
3BKO BL31, genes involved with the regulation of apoptosis were
among the most significantly altered in 3BKO LCLs. Additionally
genes involved with cell migration and its regulation, and
membrane expression (signal-anchor, glycoprotein, membrane
and Golgi localisation) were also enriched, with 43.8% of the
regulated genes being tagged by the keyword ‘membrane’ in
Uniprot annotation (q-value=0.000068), suggesting that EBNA3B
LCLs may exhibit a distinct cell surface phenotype from wtBAC
LCLs (Figure 9 and Table S7). On the whole, the enrichment
scores are modest, and using separate up- and down-regulated
gene lists does not enhance the enrichments.
EBNA3A and EBNA3B co-operate in gene regulation in
LCLs
A recent study of LCLs generated with mutants of EBNA3A in
the same B95-8 EBV-BAC background identified nearly 300 genes
whose expression differed from wild-type LCLs. This study used
two EBNA3A mutants [lacking either the whole gene (3AmutB) or
just the second exon (3AmutA)] which differed somewhat in the
genes they regulated (not shown). For a rational comparison with
our cell lines, which are complete EBNA3A knockouts, we have
identified the genes differentially regulated between 3AmutB and
WT LCLs from the published microarray data.
Comparing these genes (having filtered our array data to
include only genes represented in the U133 microarray that was
used for the mutB LCLs), we see a modest overlap (23% of the
BL31 group) in genes derepressed by EBNA3A deletion in both
cell types but very little overlap for genes whose expression falls in
3AKO LCLs (Figure 10A). These genes include the aforemen-
tioned NOTCH2 as well as PRKCA, HDAC9, TNFRSF10 (TRAIL),
BMP4 and the vitamin A transporter SLC23A2 (Table S7).
The overlap between the EBNA3A mutant and 3BKO LCLs is
substantial for genes whose expression rose in the mutants, with 20
of 72 (around 25%) of the 3B-repressed genes also being
derepressed in EBNA3A mutant LCLs for at least one probeset
(Figure 10). Expressed as a proportion of 3A-regulated genes (20 of
136) this proportion is considerably smaller, but unlike 3BKO-
LCLs, the EBNA3A mutant LCLs have impaired growth rates and
increased levels of pro-apoptotic factors [10,11], so many of the
additional differences could be due to alterations in gene
expression associated with these changes.
The proportion of genes up-regulated in both mutants is
smaller, only six of 60 (10%), with a further three genes being up in
one line and down in the other. All these genes, (plus three which
marginally fail the significance test for mutB but are significant
when all the 3A mutants are treated as a single group) are
summarised in Table 1. Looking at the expression data for these
genes in BL31 cell lines provides additional indicators as to their
regulation.
Discussion
Our analysis of EBNA3 function in regulating host gene
expression has been undertaken in two cell backgrounds. BL31 is a
Burkitt’s lymphoma-derived post-germinal centre B-cell line. In
contrast, LCLs are derived from the infection of naı ¨ve resting B-
cells, relying on the functions of EBV to transform and
immortalise the infected cell. These two backgrounds offer
different advantages and drawbacks that should be borne in mind
when considering the implications of the microarray data. In
BL31, EBV is operating in a background where various signalling
and transcriptional pathways are likely to have been distorted
during oncogenesis and cell line outgrowth, most notably the
constitutive activation of the c-Myc oncogene characteristic of BL.
However, functions of EBV are not required for the proliferation
of these cells, which allows the analysis of any EBV mutant
capable of generating infectious particles and persisting episom-
ally. In contrast, LCLs are much closer to the physiological
situation of infected B cells. However, the reliance on EBV’s
immortalizing ability prevents study of 3CKO and E3KO mutant
viruses, as LCLs could not be established with these viruses (data
not shown). Additionally, the impaired outgrowth and prolifera-
tion of 3AKO LCLs complicates the analysis [10,11], in contrast
to the robust growth of 3BKO and wtBAC LCLs. Culture-specific
selection pressures also distort the expression profile of LCLs as
they adapt to culture conditions [51]. Additionally, mutant-specific
selection pressures can differ from wild-type, as cells compensate
for missing transforming functions (see for example [11]). Indeed,
any stable cell system can suffer from this issue.
The chief alternative to stable cell lines is to study conditional,
inducible or knockout systems. While some of these have been
usefully applied to gene expression studies of EBNA2 (albeit with
considerable differences in the genes identified by the studies)
[52,53,54], the conditional EBNA3C is very slow to switch off, is
then degraded, and may not retain completely wild-type function
[11,55]. This complicates experimental design and interpretation.
Additionally, the EBNA3s are associated with establishing
epigenetic repression [26], so in trying to identify key transcrip-
tional targets it is important to vary EBNA3 expression during the
Figure 5. Expression and epigenetic marks associated with a gene regulated by EBNA3B and EBNA3C; RASGRP1. (A) Dotplot
visualisation of expression level values of individual BL31 cell lines. EBV mutant used to generate the cell line is indicated below and colour-coded
(BL31 indicates EBV-negative BL31 cell lines). Y axis shows expression level (MMBGX gene level analysis) on a log2 scale (ie each unit change indicates
a doubling). (B) Schematic representation showing the location of ChIP qPCR assays relative to the transcriptional start site of the RASGRP1 promoter.
(C-E) Bar charts indicate the percentage of input DNA recovered for each assay and each cell line for ChIPs using antibodies against trimethylated
H3K4 (C), trimethylated H3K27 (D), and acetylated H3K9 (E). Numbers 21t o24 relate to the assay position. Numbers below these are the clone IDs
of the cell lines used.
doi:10.1371/journal.pone.0013979.g005
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occurs early during infection).
It is with these caveats in mind that we consider our findings.
Technically, the microarray gene level expression estimates made
by MMBGX appear robust and, if anything, highlight inadequa-
cies in the qPCR assays used to validate them (Figures 2 and S4),
with the failure to detect hTERT mRNA in wtBAC-LCLs the only
exception. We also generated expression data at the transcript
level, but the large numbers of annotated transcripts, many of
which appear to be partial, appears to have compromised this
approach. Analysis of potential alternate transcripts by qPCR
suggests that these data can offer an indication of which transcript
isoforms are used, but is not a reliable measure of the relative
magnitude of these effects (see Supporting Information File S1 and
Figure S5).
To support this refinement, and allow our data to be
interrogated on a gene-by-gene basis, at both the gene and
transcript level, we have generated dotplots of the raw MMBGX
output data (as seen in Figures 5A, 6A and 7A) for each gene/
transcript and made them available at www.epstein-barrvirus.org.
uk. Here, users can type the name of their gene of interest to
visualise the gene- and transcript-level expression data for the
BL31 and LCL cell lines analysed in our lab, and of the U133
microarray data from the EBNA3A mutant-LCLs produced in the
Kempkes lab [10].
Reassuringly, the transcriptome data from the wild-type and
revertant cell lines and the EBNA3B and EBNA3C and newly
generated E3KO mutants clustered by their virus type but the two
pairs of 3AKO cell lines appear rather distinct (Figure S2). Two of
these lines (BL31-3AKO-1.1 and -1.2) were generated in unsup-
plemented media by a low titre virus stock, and took over two
months to establish. This combination may have resulted in a
powerful selection pressure that has prevented the manifestation of
some changes associated with the deletion of EBNA3A in the
presence of supplemented medium. This phenomenon can be seen
in the dotplot for RASGRP1 (Figure 5A) in which the two older cell
lines express very low levels of the transcript, whereas the other two
(BL31-3AKO-3 and -4) express higher transcript levels. This
transcriptional difference is also reflected in the H3K27 trimethyla-
tion of the locus, with 3AKO-3 exhibiting lower levels than 3AKO-
1.1(Figure 5D).Formost loci(e.g.TOX,NOTCH2- Figures6 and7)
the difference does not occur, but we have not identified any
alteration in EBV gene expression, or any other cause of this
anomaly, just as the mechanism for the gene expression differences
between 3AmutA and 3AmutB remains unclear [10].
We have previously shown the requirement for both EBNA3A
and EBNA3C in the repression of the pro-apoptotic BH3 protein
BIM by EBV [26,42] and of p16
INK4A expression in LCLs [11].
Here we find that this requirement for multiple EBNA3 proteins
for gene regulation is extremely common (as visualised in figure 3)
- around half of the genes whose expression is altered by deletion
of each EBNA3 gene also being altered by deletion of at least one
other (Figure 1). Direct interaction between EBNA3s in mediating
these effects seems likely since, when over-expressed, the EBNA3s
all partially co-localise with each other by immunofluorescence
[56,57], while a yeast-2-hybrid screen identified EBNA3A and
EBNA3C as interaction partners [58].
The repression of both the BIM (BCL2L11A) and p16
INK4A
(CDKN2A) genes by EBNA3A and EBNA3C is marked by H3K27
trimethylation [11,26], an epigenetic modification mediated by the
polycomb complex PRC-2 [27,59]. To extend our analysis of the
epigenetic state of EBNA3-regulated genes, we selected one gene
repressed by each co-operating group, where the mean fold
change in expression for each mutant was about the same (3B+3C,
3A+3C and 3A+3B+3C, represented by RASGRP1, NOTCH2 and
TOX respectively). We observed a good correlation between gene
repression and the repressive mark H3K27 trimethylation
(Figures 5D, 6D and 7D), suggesting that EBNA3B, as well as
EBNAs 3A and 3C, is involved in repression through polycomb
recruitment. Although EBNA3C is required for the repression of
the genes for which ChIP data are presented here, it is not a
requirement for EBV-related repression per se - loss of repression of
INPP5F in 3BKO BL31 cells is also characterised by reduced
H3K27 trimethylation (data not shown).
In contrast, one mark of activation, H3K4 trimethylation, is
present but appears largely unchanged (Figures 5C, 6C and 7C),
while H3K9 acetylation tracks gene activation for TOX and
RASGRP1 but not for NOTCH2 (Figures 5E, 6E and 7E). This
pattern of repressed genes being marked with both H3K27 and
H3K4 trimethylation, which we also observed on the p16
INK4A
promoter [11], is termed a ‘bivalent’ or ‘poised’ chromatin domain
and has been identified in association with developmentally
regulated genes in embryonic stem cells [60]. It will be intriguing
to establish the extent to which EBNA3-regulated genes are
epigenetically modified, whether the poised epigenetic state is
typical, and whether genes that require the EBNA3s for their
activation by EBV share this modification pattern or exhibit a
distinct epigenetic mark.
Since we are examining the steady-state expression level of EBV
genes, it is difficult to establish whether the differentially regulated
genes are direct EBNA3 targets or are altered by indirect effects.
Based on our examinations so far, we can hypothesize that genes
repressed by the EBNA3s are likely characterised by H3K27
trimethylation, at least where combinations involving EBNA3C
are involved. However, EBV activated genes and those apparently
requiring single EBNA3s for their regulation remain untested.
Global exploration of the epigenome of these cells should help
clarify the regulatory mechanisms of the EBNA3s.
While EBV-infected BL31 and LCL cells both resemble
activated blasts, they have approached this phenotype from
opposite ends of the germinal centre reaction. This reprogram-
ming of differentiation state is evident in BL31 both in the
alteration of many transcription factors (Figure 4; Table S3) and
the enrichment for germinal centre transit genes (Table S4). For
instance, EBNA3B and EBNA3C appear to be essential for the
repression of the key germinal centre transcription factor BCL6,o f
its co-repressor and interaction partner BACH2 [61], and of
NFATC2 in EBV-infected BL31 cells, with mutants showing over
10-fold increase in expression. BACH2 is repressed upon infection
of naı ¨ve B cells [62], and is derepressed in 3AmutB (but not
3BKO) LCLs. Notably, genes whose expression change in
different directions in 3BKO-BL31 and -LCLs also differ in
expression between naı ¨ve B-cells and centroblasts. This hints that
EBNA3B may be manipulating some aspects of the germinal
Figure 6. Expression and epigenetic marks associated with a gene regulated by EBNA3A and EBNA3C; NOTCH2. (A). Dotplot
visualisation of expression level values of individual BL31 cell lines as described for figure 5A (B). Schematic representation indicates of location of
ChIP qPCR assays relative to the transcriptional start site of the NOTCH2 promoter. (C-E) Bar charts indicate the percentage of input DNA recovered
for each assay and each cell line, for ChIPs using antibodies against trimethylated H3K4 (C), trimethylated H3K27 (D), and acetylated H3K9 (E).
Numbers +1t o23 relate to the assay position. Numbers below these are the clone IDs of the cell lines used.
doi:10.1371/journal.pone.0013979.g006
Gene Regulation by EBV EBNA3s
PLoS ONE | www.plosone.org 10 November 2010 | Volume 5 | Issue 11 | e13979Gene Regulation by EBV EBNA3s
PLoS ONE | www.plosone.org 11 November 2010 | Volume 5 | Issue 11 | e13979centre transition, which is central to the in vivo latency program of
EBV [4,6].
The most striking functional correlation from the array data was
the subtle but widespread and highly significant repressive effect of
EBNA3C on genes associated with mitosis (Figure 3, Table S2).
EBNA3C over-expression is known to be able to deregulate the
cell cycle, overcoming checkpoints, resulting in aberrant mitosis
and cytokinesis [28,30,32,63]. EBV itself has been shown to
protect infected cells from drugs that induce cell cycle arrest in
mitotic metaphase [42]. Perhaps this alteration in the balance of
mitotic proteins is a subtle manifestation of these effects.
Given the unimportance of EBNA3B in the immortalisation
process, coupled to the large number of genes whose expression it
appears to alter, it is likely that it has a crucial function in vivo, such
as mobilizing the infected cell to the germinal centre or once there
for the process of germinal centre transition, and perhaps the
associated switch from the latency III to latency II gene expression
program of EBV. Since the germinal centre process is mediated by
cell-cell contact and communication, it is notable that a large
number of chemokine (CCL20, CCL25, CXCL10, IL10, IL19),
chemokine receptor (CXCR7, CCR4, CCR, IL6R and previously
identified CXCL4 [13]) and integrin (ITGB1, ITGB3, ITGBL1 and
ITGAL) genes significantly altered in 3BKO LCLs.
Aside from the 3Amut LCLs that we have included in our
analysis, only two previous microarrays studying EBNA3 gene
regulation have been published. Our analysis in IMR-90
fibroblasts (which convinced us of the need to study EBNA3s in
the context of virus infection) identified a selection of chaperones
and their regulator BAG3 as EBNA3A targets [41]. Refreshingly,
BAG3 expression is also altered in 3BKO and 3AmutB LCLs . The
more relevant study used an insertional mutant of EBNA3B in the
EBV-BAC to generate an EBNA3B-knockout LCL [13] that also
exhibited compromised EBNA3C expression in the resulting LCLs
(3B
-/3C
low LCLs ). This disparity was used to attribute gene
regulation to EBNA3B or EBNA3C. Our 3BKO LCLs express
normal EBNA3C levels (Figure S1) but deletion of EBNA3B alters
the regulation of all but one (JAG1) of these genes, albeit a
relatively small effect for ITGA4 and FLNA (summarised in Table
S9). That is not to say that EBNA3C plays no role in the
regulation of TCL1A or NCALD – the overriding finding of our
study is that many genes require multiple EBNA3 proteins for
their regulation, and Hertle et al. previously observed that CXCR4,
NCALD and ENTH (CLINT1) are differentially regulated in both
EBNA3A mutant and 3B/3C
low LCLs [10]. We have identified 30
additional genes that appear to require both EBNA3A and
EBNA3B (Table 1), although relaxing significance thresholds
reveals further potential examples that could be tested by analysis
of additional cell lines. In BL31 few (if any) genes require only
EBNA3A and EBNA3B for their regulation, so we would predict
that EBV’s regulation of most of these genes will also require
EBNA3C.
The comparison between genes regulated by EBNA3B and
EBNA3A in BL31 and LCLs shows a rather limited set of genes to
be differentially regulated in both systems (Figures 8 & 10), with
only about 25% of genes altered in LCLs changed in the
corresponding BL31 cell. This may be a consequence (as detailed
above) of the underlying mutations that drove the original
transformation and immortalisation of the parental BL31 cell
line, clonal selection pressures associated with establishing LCLs,
and the alternative differentiation states of the two cell types.
However, where genes are regulated in both cell types the BL31
data can predict features required for their mechanism of
regulation in LCLs. For instance, 14 of the 21 genes up-regulated
in both 3AmutB and 3BKO LCLs are also regulated by EBNA3s
in BL31 (Table 1), and this allows us to predict that CASP8, CDH1,
FLOT1, SLC23A2, and WWC3 are likely to also require EBNA3C
for their repression in LCLs, while ADARB1, BAG3, CREB5,
HHEX and LILRA4 will not. The BL31 data also support the
opposed effect of EBNA3A and EBNA3B on expression of
ST3GAL5 and PTAFR, as the same direction of change is seen in
both LCL and BL31, supporting the statistical confidence for
expression of these genes, and further illustrating the complex
nature of the interactions between the EBNA3s and the host cell
transcriptome.
As well as looking at the gene expression data as a whole,
combining the BL31 data with the LCL data identifies a number
of genes of interest (Tables 1, S6 and S8). For instance, TCL1A has
been suggested as a key EBNA3C-regulated transforming gene
Figure 7. Expression and epigenetic marks associated with a gene regulated by EBNA3A, EBNA3B and EBNA3C; TOX. (A) Dotplot
visualisation of expression level values of individual BL31 cell lines as described for figure 5A (B). Schematic representation indicates of location of
chromatin immunoprecipitation primer assays relative to the transcriptional start site of TOX promoter. (C-E) Bar charts indicate the percentage of
input DNA recovered for each assay and each cell line, for ChIPs using antibodies against trimethylated H3K4 (C), trimethylated H3K27 (D), and
acetylated H3K9 (E). Numbers +2t o22 relate to the assay position. Numbers below these are the clone IDs of the cell lines used.
doi:10.1371/journal.pone.0013979.g007
Figure 8. Overlap in EBNA3B-regulated genes between LCL
and BL31 cell lines. Venn diagram showing overlaps of genes whose
regulation changes more than two-fold (p,0.001). The top two sets are
of genes more highly expressed in the EBNA3B knockout cell lines than
wtBAC cells; bottom two are down-regulated in 3BKO lines as labelled.
The identities of the genes differentially expressed in both 3BKO BL31
and LCLs, and their ANOVA statistics are given in Table S6.
doi:10.1371/journal.pone.0013979.g008
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PLoS ONE | www.plosone.org 12 November 2010 | Volume 5 | Issue 11 | e13979Figure 9. Ontological groupings of EBNA3B-regulated genes in LCLs. MMBGX-extracted gene expression levels were normalised to the
mean and scaled by the standard deviation of gene expression levels in LCLs for each gene, and coloured by relative expression (see scale). These
were grouped by ontological term, and where genes fell into multiple groups, they were placed in the group in the following order - apoptosis, cell
migration, chemotaxis and then hemopoesis/activation. Genes within each group were ordered by unsupervised clustering. Cell clone IDs are
indicated at the top of the apoptosis heatmap and are in the same sequence for other categories.
doi:10.1371/journal.pone.0013979.g009
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observed the expression level to increase in both wtBAC and
3BKO LCLs as the cells age (data not shown), supporting other
evidence for its role in culture adaptation of LCLs rather than
transformation [51]. In contrast, EBV suppresses TERT (the
protein component of telomerase) in both BL31 and LCLs, with
some evidence for a role for all of the EBNA3s in its repression.
Up-regulation of telomerase appears important for the true
immortalisation of transformed lymphocytes [65]. Given that
primary B-cells normally express only low levels of TERT [66], we
suggest that the EBNA3s are suppressing the action of a second
factor that up-regulates TERT, such as LMP1 [67,68] or c-Myc
[69]. NOTCH2 is central to the development of marginal zone
(IgM
+IgD
+CD27
+) B-cells [70], and its repression by EBNA3A
and EBNA3C (Figure 6) may be the reason that EBV absent from
this part of the memory B cell pool in vivo [71].
The co-operation between EBV genes extends beyond the
EBNA3s. Interactome studies suggest that interaction between
EBV proteins (and those of other herpesviruses) is the norm
[58,72]. But despite knowing that EBNA-LP and EBNA2 co-
operate in transcriptional regulation [73,74,75] (and EBNA3A can
interact with both [18,58]), even the EBNA2 transactivation
studies in an EBV-positive background lack a wild-type EBNA-LP
[76], which seems an unfortunate oversight. Both EBNA2 and the
EBNA3s can interact with DNA through their common binding
partner CBF1 (RBPJk), with the over-expression of the EBNA3
proteins able to repress EBNA2-driven activation
[16,17,18,77,78]. Whether this phenomenon also occurs in
EBV-infected cells is not known. Some of the genes that are
derepressed in 3BKO LCLs (CXCR7, TESC, CCR7, CDH1 and
ASCL1) are induced by EBNA2-ER reactivation in EREB cells
[52,53]. In contrast, RAPGEF2 which is up-regulated by EBNA2-
ER in the absence of CBF1 [54] also requires EBNA3s for its up-
regulation by EBV in BL31 cells (and is not increased in 3BKO
LCLs (Tables S1 and S5). This implies that EBNA2 and the
EBNA3s may co-operate in RAPGEF2 up-regulation, suggesting a
model whereby EBNA2 target genes not requiring CBF1 for their
modulation might exhibit co-operation rather than competition
with EBNA3s.
There are undoubtedly additional observations that could be
extracted from further study of these microarray data. Above all,
we suggest that the interconnected nature of virus gene function
makes it imperative that, where possible, gene expression studies
should take place in the context of the whole viral genome. The
EBNA3s appear to be central to the regulation of host gene
expression by EBV, being involved in altering at least half of the
genes regulated by EBV in BL31 cells, and that H3K27
trimethylation by the polycomb complex is central to the
repression of genes by the EBNA3s. Our global approach supports
a role for the EBNA3s in altering apoptotic potential and cell
differentiation state, and suggests that EBNA3C subtly changes the
balance of mitotic gene expression. EBNA3B is shown to be a
surprisingly important contributor to the modulation of host genes.
The microarray data suggest a number of high quality candidates
for the mediation of EBV’s effects, exploration of which should
lead to the further elucidation of EBNA3 function, while further
global studies are required to untangle the way in which complex
interactions between the EBV gene products manipulate the host
cell.
Materials and Methods
Generation of recombinant EBV, EBV-positive cell lines
and cell culture conditions
The EBNA3A, EBNA3B and EBNA3C-exon2 deleted viruses
(herein named respectively 3AKO, 3BKO and 3CKO), and their
revertants (respectively 3Arev, 3Brev and 3Crev), have been
described previously [42]. We have additionally generated a
mutant EBV lacking all three EBNA3 genes (E3KO) and its
revertant (E3rev) using previously described methods [79]. This
corresponds to a deletion starting at the same point as in 3AKO
and ending at the end of the 3CKO deletion - positions 92310–
100998 of the B95-8 strain of EBV (Accession No V01555). These
EBV-BACs were transfected into HEK-293 cells (ATCC, CRL-
1573), grown in RPMI supplemented with 10% FCS, and selected
in 150 mg/ml Hygromycin B. All BAC constructs have been
validated by pulsed field gel electrophoresis: EcoRI and NotI digests
showed the parental EBV-B95-8 BAC (wtBAC) and all the
Figure 10. Consistency between 3AKO BL31 and LCLs, and co-operation between EBNA3B and EBNA3A in LCLs. Venn diagrams
indicate overlap between genes differentially regulated [i.e. with a minimum fold change of 2 and p,0.001] in (A) 3AmutB LCLs and 3AKO BL31; and
(B) 3AmutB and 3BKO LCLs. Numbers of genes are indicated in the sets and the size of each set indicated below the set name. For 3AmutB this is
denoted as ‘‘(no of probesets/no of unique gene IDs)’’. The 3AKO-BL31 and 3BKO-LCL sets exclude genes not represented in the U133 Plus2
microarray that was used to generate the 3AmutB LCL data.
doi:10.1371/journal.pone.0013979.g010
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3BKO vs wtBAC
U133
probeset ID 3AmutB vs WT BL31 Changes
Ensembl Gene ID Gene Name p-value Fold-Change p-value Fold-Change
ENSG00000224220 AC104699.2 0.0008284 22.01 215565_at 0.0000363 24.76 EBV activates; no EBNA3 effect
ENSG00000102760 C13orf15 0.0000037 24.69 218723_s_at 0.0000522 24.20 None
ENSG00000064763 FAR2 0.0000123 29.05 220615_s_at 0.0001155 25.13 Not significant
ENSG00000089692 LAG3 0.0004815 23.63 206486_at 0.0042367 23.12 None
ENSG00000070759 TESK2 0.0008605 22.18 205486_at 0.0000122 22.91 3AKO, 3BKO and 3CKO down ,2-fold
ENSG00000181458 TMEM45A 0.0000045 22.10 219410_at 0.0000083 210.53 None
ENSG00000121858 TNFSF10 0.0002546 22.28 202687_s_at 0.0001065 23.51 3AKo and 3BKO up
202688_at 0.0001249 28.98
214329_x_at 0.0014427 22.03
ENSG00000197381 ADARB1 0.0005489 6.49 203865_s_at 0.0000001 7.45 3BKO up 6x
207999_s_at 0.2306420 1.14
209979_at 0.5874880 1.06
ENSG00000084234 APLP2 0.0000116 2.82 208248_x_at 0.0000074 2.96 None
208702_x_at 0.0002423 2.08
214875_x_at 0.0000891 2.15
211404_s_at 0.0000544 2.50
208704_x_at 0.0001191 2.58
208703_s_at 0.0007441 3.05
ENSG00000139352 ASCL1 0.0000428 26.68 213768_s_at 0.0001322 3.99 None
209985_s_at 0.0006246 1.51
209987_s_at 0.0009894 6.68
209988_s_at 0.0064834 6.19
ENSG00000151929 BAG3 0.0000045 8.60 217911_s_at 0.0000022 5.62 3BKO up
ENSG00000064012 CASP8 0.0000325 2.29 213373_s_at 0.0000005 4.54 3AKO, 3BKO and 3CKO up 1.5-1.8x
207686_s_at 0.0003986 3.89
ENSG00000115009 CCL20 0.0001118 4.61 205476_at 0.0005208 17.27 None
ENSG00000081377 CDC14B 0.0000240 5.09 221556_at 0.0000014 10.98 None
208022_s_at 0.0000405 5.16
221555_x_at 0.0001045 3.50
211348_s_at 0.0135807 1.21
211347_at 0.0496798 1.16
216284_at 0.4095960 1.06
ENSG00000039068 CDH1 0.0000552 6.85 201131_s_at 0.0001482 9.01 3AKO, 3BKO and 3CKO down 2x
(marginal significance)
201130_s_at 0.0137153 2.22
ENSG00000146592 CREB5 0.0000003 11.14 205931_s_at 0.0000181 5.18 3BKO up
ENSG00000197872 FAM49A 0.0000665 12.68 208092_s_at 0.0000001 16.97 3AKO up
209683_at 0.0000001 14.07
ENSG00000132589 FLOT2 0.0000025 3.83 201350_at 0.0002471 3.17 3B 3C 1.3-1.6x
211299_s_at 0.0002721 3.26
ENSG00000152804 HHEX 0.0000072 19.30 215933_s_at 0.0000263 6.60 3BKO and 2 of 4 3AKO up
204689_at 0.0011165 3.73
ENSG00000198825 INPP5F 0.0000005 23.56 203607_at 0.0000003 11.10 3BKO up 20x; 3CKO up 2x
ENSG00000239961 LILRA4 0.0003930 5.15 210313_at 0.0000011 6.00 3BKO up
ENSG00000049759 NEDD4L 0.0000795 2.84 212448_at 0.0000537 2.06 E3KO and BL31 down 3.5x
212445_s_at 0.0014747 2.81
ENSG00000100784 RPS6KA5 0.0003159 3.16 204633_s_at 0.0007989 2.00 None
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parental BAC and in episomes rescued from the producer cell line
([42] and data not shown).
Transfection of 293 producer clones with BALF4 and BZLF1
expression plasmids produced infectious recombinant viruses as
described previously [80]. Virus from independently generated
293 producer clones was used to infect the EBV-negative Burkitt’s
lymphoma cell line BL31 [81]. Newly infected BL31 cell lines were
grown out and propagated in RPMI supplemented with 1mM
sodium pyruvate, 50 mM thioglycerol, 10% FCS, penicillin and
streptomycin and selected with 200 mg/ml Hygromycin B. Once
established, Hygromycin B concentration was reduced to 125 mg/
ml. Previously described BL31 cells were grown in RPMI
supplemented with 10% FCS, penicillin and streptomycin. BL31
cell lines were split 1:3 twice a week to maintain growth in culture.
To generate LCLs using B95-8-BAC (wtBAC) and EBNA3B
knockout (3BKO) viruses, we infected 10
6 peripheral blood
leukocytes (PBLs) with 100 ml of virus preparation (at between
50 and 300 Raji-green-units per microlitre). The PBLs for
generating the LCLs came from three EBV-negative blood donors
(kind gift from Dr Ingo Johannessen, University of Edinburgh)
designated D1, D2 and D3. For each donor, PBLs were infected
with virus from two independent HEK-293 cell lines carrying the
parental B95-8 BAC and from two 3BKO producer lines carrying
the EBNA3B knockout BAC (3BKO). LCLs were grown out from
these infections in RPMI supplemented with 15% FCS, and once
sufficient cells had been established (typically 3–6 weeks post
infection), they were seeded at 5610
5 cells per ml. After 24 hours,
15 ml of cells were harvested for RNA isolation.
Microarray analysis
BL31 cell lines were grown for 48 hours after splitting 1:3 and
then RNA was extracted from 30 ml of cell culture using a Qiagen
RNeasy Midi kit according to manufacturer’s protocol. Where
RNA was less than 500 ng/ml it was concentrated by precipitation
with sodium acetate and ethanol. LCLs were seeded at 5610
5 cells
per ml,15 ml harvested 24 hours later and RNA isolated using
Qiagen RNeasy mini kit as instructed. RNA was quantified by
NanoDrop spectrophotometer (Thermo Scientific) and checked
for integrity on a Bioanalyzer (Agilent). RNA was labelled using
the GeneChip Affymetrix whole transcript sense target labelling
assay. Essentially this comprises a ribosomal RNA reduction step
using the Ribominus human transcriptome isolation kit (Invitro-
gen), and generation of labelled sense-strand cDNA. This was then
hybridised to an Affymetrix Human Exon 1.0ST array and
scanned.
Array data was extracted using Expression Console software to
generate CEL files. CEL files were summarised with MMBGX
(Multi-Mapping Bayesian Gene eXpression) v0.99.5 using the
X:Map/Ensembl database for Homo Sapiens (GRCh37) v56
(xmap_homo_sapiens_core_56_37a.tgz). MMBGX uses X:Map
mappings between probes and transcripts encoded in Ensembl
cDNA sequences to generate Exon array probesets [46].
MicroRNA sequences are not included in the cDNA tables, but
3BKO vs wtBAC
U133
probeset ID 3AmutB vs WT BL31 Changes
Ensembl Gene ID Gene Name p-value Fold-Change p-value Fold-Change
204635_at 0.0597242 1.42
ENSG00000089057 SLC23A2 0.0000042 8.46 209237_s_at 0.0000344 3.08 3BKO up 5x; 3AKO and 3CKO up 3x
211572_s_at 0.0001151 3.85
209236_at 0.0000987 3.42
ENSG00000088992 TESC 0.0001774 3.12 218872_at 0.0017321 4.27 3CKO down 5x
ENSG00000111962 UST 0.0003600 4.55 205138_s_at 0.0000059 3.25 EBV infection up 10x; 3BKO up 2x
more and 3AKO down (not significant)
205139_s_at 0.0000124 9.74
ENSG00000047644 WWC3 0.0000148 3.92 219520_s_at 0.0004171 2.45 3BKO and 3CKO up
ENSG00000093100 XXbac-B461K10.1 0.0000028 7.15 212715_s_at 0.0000550 2.80 3BKO up
ENSG00000169245 CXCL10 0.0009958 27.89 204533_at 0.0000000 37.04 3BKO 3CKO and 2 of 3AKO down .4x
ENSG00000185432 METTL7A 0.0000215 23.50 207761_s_at 0.0023597 6.08 3BKO down
209703_x_at 0.5304590 1.06
ENSG00000115525 ST3GAL5 0.0000387 6.68 203217_s_at 0.0001469 22.48 3AKO down 3BKO up marginal
significance
ENSG00000169403 PTAFR 0.0000137 8.45 211661_x_at 0.0004363 22.83 3BKO up 1.4x; 3AKO down 1.7x
206278_at 0.0361156 21.27
Genes are grouped into those down-regulated in EBNA3A and 3B knockout LCLs (top part), up-regulated in both (middle), and regulated in different directions in the
two mutants (Bottom). For each gene, data for all of the Affymetrix U133plus2 probesets mapped to that gene are included. ANOVA p-values and fold changes are
shown for 3BKO-LCL vs wtBAC LCL and for 3AmutB LCL vs WT LCL. Affymetrix IDs are bold where p,0.001 and fold change .1.5. Data are bold where p,0.001 or fold
change .2.
Genes in italics passed significance thresholds for all EBAN3A mutants vs WT, but not quite for 3AmutB vs WT. The changes seen in the gene’s expression in BL31 cells are
indicated in the final column.
doi:10.1371/journal.pone.0013979.t001
Table 1. Cont.
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additional probesets targeting microRNAs and included these in
our analysis. Mean posterior expression estimates for each gene
were log2 transformed. The CEL files and gene level MMBGX
estimates are deposited in the EBI ArrayExpress database (http://
www.ebi.ac.uk/microarray-as/ae/) with accession ID E-MEXP-
2767 for the BL31 data and E-MEXP-2768 for 3BKO and
wtBAC LCLs. Processed microarray data from the EBNA3A
LCLs (deposited at EBI Array Express with accession ID E-
GEOD-17908)[10]) was log2 transformed before further analysis
and annotated according to the Ensembl v56 annotation of the
probesets obtained using Biomart, to facilitate comparison with the
exon array data.
Subsequent analyses (principle component analysis, ANOVA,
false discovery rate calculation, clustering etc) were performed
using Partek Genomic Suite version 6.4 or 6.5 except where stated
otherwise. Generally, statistical analyses were performed using the
default settings. Hierarchical clustering was performed using
average linkage and Euclidian dissimilarity in a 2-pass method.
Differentially regulated genes were defined by ANOVA. In
order to establish the best model for experimental and batch
effects, a series of ANOVAs were used to assess the contribution of
different sources of error (potential causes of batch effects are
described in the array annotation deposited with the raw
microarray data). Essentially, the model that best fit the data
(i.e. the error was the smallest contributor to the source of
variation in the system) was a 3-way ANOVA incorporating the
media type in which the cells were grown and the microarray lot
number used for the sample. False discovery rate analyses on the
p-values of factors in the various ANOVAs confirmed that other
factors caused no more variation than chance.
Differentially regulated genes in 3Amut LCLs and 3BKO LCLs
were identified using an ANOVA model including the donor ID
(for genetic background of the cells). For comparison of 3BKO and
3Amut LCLs, the Exon array gene list was reduced to include only
genes represented on the U133 array (see Supporting Information
File S1 for details). For comparison, the genes differentially
regulated between 3BmutB and wtBAC were used, as 3AmutB is
the most similar to our 3AKO virus.
Gene Ontology
Grouping for ontologically similar genes was assessed using the
Database for Annotation, Visualization and Integrated Discovery
(DAVID) version 6.7. Specifically, for each contrast between an
EBNA3 knockout and the wild-type-infected cells, lists of genes
were generated whose members passed one of the following
threshold combinations: p,0.0001 and fold change .1.3 or
p,0.001 and fold change .2o rp ,0.01 fold change .3. These
were analysed for up and down-regulated genes both separately
and together, and functional annotation groups were identified
both with and without clustering (at medium stringency). The
significance of any ontological label is presented either as false
discovery rate q-value according to Benjamini (from the DAVID
functional annotation chart) or as a group enrichment score (the
negative log of the geometric mean of the group’s members’ EASE
p-values - tables S2 and S7) from the functional annotation
clustering.
Western Blot analysis and generation of anti-EBNA3B
antibody 6C9
Western blots were performed using minigels (Bio-Rad) as
described previously [42]. Primary antibodies used were as follows:
mouse monoclonal antibodies against EBNA2 (clone PE2;
DAKO), LMP1 (CS1-4; DAKO), EBNA3C (A-10: hybridoma a
gift of Martin Rowe), EBNA-LP (JF186 [82]), gamma-tubulin
(GTU-88, Sigma). Sheep polyclonal antibody against EBNA3A
(ExAlpha, Maynard MA USA).
For detection of EBNA3B, we have raised a rat monoclonal
antibody (clone 6C9) against amino-acids 328–624 of EBNA3B
fused to GST. A HincII/MseI fragment of of the EBNA3B cDNA
was ligated in-frame into the pGEX-3X GST-fusion vector. The
resulting fusion protein was purified from lysates of E. Coli on
glutathione-sepharose beads and used for immunisation of rats as
described previously [83].
Real-time quantitative PCR (qPCR)
Validation of the microarray data was achieved using a custom
Taqman Low Density Array card (Applied Biosystems). The assays
used are summarised in Table S10. Each 48 assay channel was
loaded with 1 ml of cDNA (generated from 750 mg of total RNA
using the SuperScriptH III First-Strand Synthesis Supermix,
Invitrogen) in TaqManH Gene Expression Master Mix (Applied
Biosystems). qRT-PCR was performed on a 7900HT fast real-time
system (Applied Biosystems) using recommended conditions, and
Ct values extracted using SDS2.3. Five reference genes were
included on the array card (ACTB, GAPDH, GNB2L1, GUSB,
HMBS) and were used to generate normalisation factors for each
sample using qBase Plus v1.4 (Biogazelle, Ghent, Netherlands)
which were used to normalise the Ct values. Relative quantities
were generated assuming an assay efficiency of 100% and
assigning a value of 1 to a normalised Ct of 40 (ie no qPCR
amplification). These quantities were also analysed by ANOVA,
applying the same model as used for the microarray.
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were carried out as described previously [26] using
a ChIP Assay Kit (17–295; Millipore) according to the
manufacturer’s instructions. Chromatin was sheared to a range
of 200bp – 800bp in length from 1610
6 cells per ChIP in 200 mlo f
lysis buffer using a Bioruptor sonicator (UCD-200; Diagenode) on
a high setting for a total of 12 min (30 sec ‘on’/30 sec ‘off’
intermittent sonication). Chromatin was precipitated using anti-
H3K27me3 antibody (ChIPAb+ 17-622; Millipore) and, as a
negative control, rabbit IgG serum (PP64B; Millipore) was used.
Isolated DNA was assayed by quantitative PCR (qPCR) using the
Platinum SYBR Green qPCR SuperMix (11733; Invitrogen) and
an ABI 7900 384-well Real-Time PCR machine. The sequence of
primers used for each promoter specific PCR are attached in
Table S11. Cycling conditions used were: 2 min at 50uC, 10 min
at 95uC and then 15 sec at 95uC, 1 min at 60uC for 40 cycles.
Using standard curves, 1% of input was compared to the IP
sample and the values from the IgG negative control were
subtracted as background. The data are representative of two
independent experiments and are given as means 6 1SD for
triplicate PCRs.
Supporting Information
File S1 Gene set enrichment analysis shows EBNA3s alter genes
involved in the germinal centre transition. Analysis of EBNA3A-
mutant LCL U133 microarray data. Transcript-level analysis of
the microarray is only indicative of differential transcript use.
Found at: doi:10.1371/journal.pone.0013979.s001 (0.06 MB
DOC)
Figure S1 EBV latent gene expression in BL31 cell lines is not
altered by EBNA3 deletion. Western blots for EBV latent proteins
expressed in the newly described cell lines are shown here. As
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latent gene expression [48].
Found at: doi:10.1371/journal.pone.0013979.s002 (1.15 MB
PDF)
Figure S2 Gene expression data clusters cell lines according to
the EBV mutant (A) 3-dimensional principle component analysis
of raw gene level expression values. Colour indicates the virus type
used and the shape indicates the growth media used. (B)
Dendrogram generated by unsupervised clustering of cell lines
based on the expression values of the subset identified as
differentially regulated (p,0.005; Fold change .2) between
EBV-negative BL31 and wild-type-infected BL31. Dendrogram
line colours match virus type in the PCA. Block colours further
distinguish the virus used (i.e. separate the different revertants
within the wtBAC group).
Found at: doi:10.1371/journal.pone.0013979.s003 (0.53 MB
PDF)
Figure S3 Protein levels of EBV latent genes are unaffected by
absence of EBN3B in LCLs. Western blots of the major EBV
latent proteins were performed on protein samples taken at the
same time as the RNA for the microarray. EBNA3A and LMP2A
westerns are on total protein extracts (cells lysed in SDS sample
buffer) while the others are from RIPA protein extracts.
Found at: doi:10.1371/journal.pone.0013979.s004 (0.56 MB
PDF)
Figure S4 Validation of 3BKO LCL microarray expression level
data by qPCR. Log2 transformed gene expression values for 42
genes for the six 3BKO LCLs and six wtBAC LCLs were
established by qPCR using the same RNA samples that were used
for the microarrays. These are plotted against the corresponding
gene level expression value from the MMBGX microarray
analysis. Correlation coefficient and best fit line are indicated.
Assays deviating from the trendline (GAPDH, ACTB, SOX4 and
TERT) are coloured as indicated.
Found at: doi:10.1371/journal.pone.0013979.s005 (0.07 MB
PDF)
Figure S5 qPCR assessment of transcript-level microarray
analysis. As candidates for assessing the transcript level analysis
of gene expression, we have looked at TERT (A-D), TSC22D1 (E)
and TNFSF10 (F) expression in 3BKO and wtBAC LCLs. In each
case the same RNA samples were used for the qPCR as for the
microarray. (A) A graphical representation (from xmap.picr.ma-
n.ac.uk) of the TERT transcript variants in ENSEMBL release 56.
Locations of probes from the Exon microarray are indicated by
vertical green lines (where they map uniquely to the genome) and
grey lines (mapping to multiple genome locations). Exons are
indicated by red boxes, and the exon junctions studied are shown.
(B-F) Box and whiskers plots, indicating median, and 25th and
75th percentile values (box) with whiskers indicating minimum and
maximum values). Y-axis scale is a log 2 gene expression level
scale, taken from the microarray or from a modified 2-delCt
calculation (see [methods]). For TERT, (B) shows transcript-level
output of the MMBGX algorithm, (C) sums the appropriate
transcripts to estimate exon-exon junction levels and (D) is
quantitation of these exon-exon junctions by qPCR. Similarly,
(E) and (F) show the estimated exon-exon junction quantities from
transcript level analysis (left - marked ‘Array’) and qPCR analysis
of these junctions (right) for TSC22D1 and TNFSF10 respectively.
Found at: doi:10.1371/journal.pone.0013979.s006 (0.71 MB
PDF)
Table S1 BL31 gene level ANOVA statistics. Complete list of all
genes with contrast statistics showing p-value and fold change of
mutant EBV-infected cell lines as compared to wtBAC-infected.
Also includes uninfected BL31 compared to wtBAC. Negative fold
change indicates lower expression level in mutant compared to
wtBAC cells.
Found at: doi:10.1371/journal.pone.0013979.s007 (9.43 MB
XLS)
Table S2 Functional groups altered by the deletion of EBNA3s
in BL31. Cluster enrichment scores (from DAVID) for lists of
genes regulated by each single EBNA3 knockout. For each
EBNA3 knockout, statistics are shown for up-regulated and down
regulated genes independently, and for these two lists combined.
The value is a negative log10 of the enrichment p-value for the
combined set of ontology groups indicated (ie high values are more
significant).
Found at: doi:10.1371/journal.pone.0013979.s008 (0.04 MB
XLSX)
Table S3 ANOVA statistics for major players in B-cell
differentiation. Contrast statistics showing statistical significance
and fold change for genes shown in Figure 4. Emphasis (bold and/
or colour) is placed where statistics pass certain thresholds as
indicated in the table.
Found at: doi:10.1371/journal.pone.0013979.s009 (0.06 MB
XLSX)
Table S4 Gene set enrichment analysis of EBV and EBNA3-
regulated genes for genes involved with the germinal centre
transition. Statistics assessing enrichment (skewing) of total exon
array data for genes differentially expressed between germinal
centre and naive and memory B cells, according to Klein et al
2003 [58]. Table shows GSEA enrichment score (NES) and q-
value (False discovery rate for chance enrichment of the gene list).
Blue figures indicates a positive correlation (more than a random
number of these these genes are expressed at a higher level in
wtBAC than the mutant/uninfected BL31 cells), red figures a
negative correlation (enrichment for genes expressed higher in the
mutant). The transition analysed is indicated at the top of the
table, and up- and down-regulated genes are treated separately.
Emphasis (colour; bold) thresholds are indicated below the table.
Found at: doi:10.1371/journal.pone.0013979.s010 (0.07 MB
XLSX)
Table S5 ANOVA statistics indicating differential gene expres-
sion between wtBAC and 3BKO LCLs. Whole genome gene-
level analysis fold change and significance for each gene. Positive
value indicates higher expression in 3BKO LCLs. The Donor
effect p-value indicates whether the expression level is signifi-
cantly affected by the different genetic background giving rise to
the LCLs. Gene list is sorted from most significantly different
gene.
Found at: doi:10.1371/journal.pone.0013979.s011 (2.36 MB
XLSX)
Table S6 ANOVA statistics for genes differentially regulated
by EBNA3B in both BL31 and LCLs. List of genes significantly
altered by EBNA3B deletion (p,0.001 and fold change .2) in
both BL31 cells and LCLs. Table is separated into three
sections (up-regulated in 3BKO cells, down-regulated, and up
in 3BKO BL31 but down in 3BKO LCLs (as per the numbers
indicated in the venn diagram in Figure 8). Genes are listed
alphabetically by name in each section. ANOVA statistics
showing the effects of other EBNA3 mutants in BL31 are
included for interest.
Found at: doi:10.1371/journal.pone.0013979.s012 (0.06 MB
XLSX)
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Cluster enrichment scores for the 3BKO-LCL differentially
expressed genes are indicated (see Table S2 for more details).
Found at: doi:10.1371/journal.pone.0013979.s013 (0.04 MB
XLSX)
Table S8 ANOVA statistics for genes differentially regulated by
EBNA3A in both BL31 and LCLs. List of genes significantly
altered by EBNA3A deletion (p,0.001 and fold change .2) in
both 3AKO-BL31 cells and 3AmutB-LCLs (according to Hertle et
al 2009). Table is separated into three sections (down-regulated in
3AKO cells, up-regulated, and up in 3AKO BL31 but down in
3AmutB LCLs (as per the numbers indicated in the venn diagram
in Figure 10A). Three additional genes are included where
3AmutB statistics marginally failed to pass the significance or fold-
change threshold, but when all 3Amut LCLs were included, they
did pass these thresholds. Statistics for all probesets in the U133
microarray mapping to the gene (according to Ensembl genome
annotation v56) are included. Those passing significance are
indicated in bold. Green indicates up-regulated in the mutant, red
indicates expressed at lower level. Genes are listed alphabetically
by name in each section.
Found at: doi:10.1371/journal.pone.0013979.s014 (0.06 MB
XLSX)
Table S9 Genes previously characterised in EBNA3B-knockout
LCLs. Fold changes previously described by Chen et al (2006) for
3B-3Clow LCLs by qPCR and U133 microarray are compared to
gene level changes from our 3BKO LCLs vs wtBAC-LCLs in our
Exon microarray. The highly significantly regulated genes
(p,0.001) by microarray are also tested by qPCR, both on the
same RNA and on an independent RNA sample. qPCR fold
changes assume assays are 100% efficient. Genes whose names
have changed since Chen et al (2006) are CLINT1 (formerly
ENTH), PIK3R5 (formerly P101-PI3K) ARL6IP5 (formerly JWA)
and TIAM1 (formerly U90902.1).
Found at: doi:10.1371/journal.pone.0013979.s015 (0.05 MB
XLSX)
Table S10 Identities of qPCR assays used to test gene
expression. All assays were used in Taqman low density array
cards (Applied Biosystems). Top array set was used for assessing
reliability of the microarrays (Figure 2 and S4). Lower list are
additional assays used to assess reliability of transctipt-level
microarray analysis (supporting information and Figure S5) Assay
details (including map of where in the gene they map are available
from the applied biosystems website.
Found at: doi:10.1371/journal.pone.0013979.s016 (0.05 MB
XLSX)
Table S11 Primers used for qPCR analysis of ChIP samples to
determine histone modification association at cellular promoters.
Position of the assay relative to transcription start site (-, upstream;
+ downstream) is indicated. Assay identifier (number -3 to +2) is as
used in Figures 5-8. ‘p’, promoter.
Found at: doi:10.1371/journal.pone.0013979.s017 (0.05 MB
XLSX)
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